
Vaxxas
Commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
* | N/A | AUD40.0m | Debt |
Total Funding | 000k |
Related Content
Vaxxas is a pioneering company in the biotechnology sector, focused on revolutionizing the way vaccines are delivered. The company has developed a novel, needle-free vaccination technology that significantly improves the efficacy and performance of both existing and next-generation vaccines. Vaxxas primarily serves healthcare providers, pharmaceutical companies, and global health organizations. Operating in the global healthcare market, Vaxxas employs a business model that includes partnerships, licensing agreements, and direct sales to generate revenue. By collaborating with renowned organizations, Vaxxas maximizes the impact of its technology on a global scale. The company's innovative approach aims to create a healthier world by making vaccinations more effective and accessible.
Keywords: biotechnology, needle-free, vaccines, healthcare, efficacy, innovation, partnerships, licensing, global health, technology.